The unmet clinical need for new molecular genetic markers in the prognosis and therapeutic management of breast cancer

Archives of Pathology and Laboratory Medicine

Volumn 129, Issue 11, 2005, Pages 1372-1374

  Hicks, David G ^a   Dawson, Andrea ^a   Mattingly, Suzanne ^b   Crowe, Joseph P ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b Exagen Diagnostics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; DNA TOPOISOMERASE (ATP HYDROLYSING) A; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TRASTUZUMAB; TUMOR MARKER;

BREAST CANCER; BREAST CARCINOGENESIS; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CHROMOSOME 17Q; DRUG TARGETING; GENE; GENE OVEREXPRESSION; GENETIC MARKER; HER2 GENE; HUMAN; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MULTIMODALITY CANCER THERAPY; PROGNOSIS; REVIEW; TOP2A GENE;

ADENOCARCINOMA; BREAST NEOPLASMS; FEMALE; GENETIC MARKERS; GENOMICS; HUMANS; PROGNOSIS;

EID: 27744492593     PISSN: 00039985     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (28)

1. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin. 2002;52:23-47.
2. Esteva FJ, Hortobagyi GN. Adjuvant systemic therapy for primary breast cancer. Surg Clin North Am. 1999;79:1075-1090.
3. Esteva FJ, Sahin AA, Cristofanilli M, et al. Molecular prognostic factors for breast cancer metastasis and survival. Semin Radiat Oncol. 2002;12:319-328.
4. Esteva FJ, Hortobagyi GN. Integration of systemic chemotherapy in the management of primary breast cancer. Oncologist. 1998;3:1-14.
5. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999;17:2639-2648.
6. Bardou VJ, Arpino G, Elledge RM, et al. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol. 2003;21:1973-1979.
7. Popescu NC, King CR, Kraus MH. Localization of the human erbB-2 gene on normal and rearranged chromosome 17 to bands q12-21.32. Genomics. 1989;4:362-366.
8. Slamon DJ, Clark GM, Wong SG, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER2/neu oncogene. Science. 1987;235:177-182.
9. Toikkanen S, Helin H, Isola J, Joensuu H. Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up. J Clin Oncol. 1992;10:1044-1048.
10. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-792.
11. Jukkola A, Bloigu R, Soini Y, Savolainen ER, Holli K, Blanco G. c-erbB-2 positivity is a factor for poor prognosis in breast cancer and poor response to hormonal or chemotherapy treatment in advanced disease. Eur J Cancer. 2001;37:347-354.
12. Mass R. The role of HER-2 expression in predicting response to therapy in breast cancer. Semin Oncol. 2000;27:46-52.
13. Toikkanen S, Helin H, Isola J, et al. Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up. J Clin Oncol. 1992;10:1044-1048.
14. Paik S, Bryant J, Park C, et al. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst. 1998;90:1361-1370.
15. Di Leo A, Gancberg D, Larsimont D, et al. HER-2 amplification and topoisomerase II alpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. Cancer Res. 2002;8:1107-1116.
16. Jarvinen TA, Tanner M, Rantanen V, et al. Amplification and deletion of topoisomerase II alpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am J Pathol. 2000;156:839-847.
17. Eifel P, Axelson JA, Costa J, et al. National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Inst. 2001;93:979-989.
18. Goldhirsch A, Wood WC, Gelber RD, et al. Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol. 2003;21:3357-3365.
19. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet. 1998;351:1451-1467.
20. Mattingly SZ. Really personal medicine: the development of genomic markers to help diagnose disease and indicate treatment is ushering in a new age. TechComm Magazine. October-November 2004:26-28.
21. Van de Vijver MJ, He YD, van't Veer LJ, et al. A gene expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002;347:1999-2009.
22. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumors. Nature. 2000;406:747-752.
23. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001;98:10869-10874.
24. Van't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002;415:530-536.
25. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351:2817-2826.
26. Cleator S, Ashworth A. Molecular profiling of breast cancer: clinical implications. Br J Cancer. 2004;90:1120-1124.
27. Sjostrom J. Predictive factors for response to chemotherapy in advanced breast cancer. Acta Oncol. 2002;41:334-345.
28. Chang JC, Woolen EC, Tsimelzon A, et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet2E 2003;362:362-369.